WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY. To request a meeting or for more details about the Conference, please reach out to your ...

Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar’s Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (Nasdaq: LAMR), one of the largest out-of-home (OOH) advertis ...

Company Overview - OptimizeRx Corp. (OPRX) currently holds a Momentum Style Score of B, indicating potential for strong performance in the momentum investing strategy [3][12] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a strong track record of outperformance in the market [4][12] Price Performance - OPRX shares have increased by 4.75% over the past week, while the Zacks Computer - Software industry has remained flat during the same period [6] - Over the past month, OPRX's price has risen by 44.56%, significantly outperforming the industry's 0.45% [6] - In the last quarter, OPRX shares rose by 23.6%, and over the past year, they have surged by 117.45%, compared to the S&P 500's increases of 9.68% and 16.9%, respectively [7] Trading Volume - The average 20-day trading volume for OPRX is 481,960 shares, which serves as a useful baseline for price-to-volume analysis [8] Earnings Outlook - In the past two months, four earnings estimates for OPRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.53 to $0.67 [10] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [10]

Core Viewpoint - OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making the Zacks rating system valuable for investors [4][6]. - The recent upgrade for OptimizeRx suggests an improvement in the company's underlying business, likely leading to increased stock prices due to investor interest [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, OptimizeRx is expected to earn $0.67 per share, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for OptimizeRx has increased by 514.3%, reflecting a significant upward trend in earnings estimates [8].

Core Insights - OptimizeRx Corp. announced organizational updates and leadership advancements aimed at accelerating its Rule of 40 strategy, which focuses on balancing sustained growth with increased profitability [1][2] Leadership Advancements - Ed Stelmakh has been appointed Chief Financial & Strategic Officer (CFSO), expanding his role to include corporate strategy alongside financial leadership, emphasizing profitable growth and shareholder value creation [3] - Theresa Greco continues as Chief Commercial Officer (CCO), overseeing the commercial team and focusing on sustainable revenue growth through a transition to a recurring revenue model [4] - Marion Odence-Ford has been named Chief Legal & Administrative Officer (CLAO), expanding her role to include oversight of key administrative functions and ensuring alignment between legal and strategic initiatives [5] - Doug Besch remains Chief Product & Technology Officer (CPTO), focusing on product enhancements and platform optimization to capture market share in pharma's commercial spend [6] - Brendan Merrell has been appointed Chief Operating Officer (COO), emphasizing operational excellence and driving operating leverage across the company [7] - Andy D'Silva has been promoted to Chief Business Officer (CBO), focusing on strategic planning and championing Rule of 40 strategies to accelerate growth initiatives [8]

[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Item 1: Financial Statements](index=4&type=section&id=Item%201%3A%20Financial%20Statements) This section presents OptimizeRx Corporation's unaudited condensed consolidated financial statements and accompanying notes for the periods ended June 30, 2025 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased slightly to **$169.3 million** as of June 30, 2025, while total liabilities decreased and stockholders' equity increased Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $54,080 | $53,971 | | Cash and cash equivalents | $16,585 | $13,380 | | Accounts receivable, net | $33,512 | $38,212 | | **Total Assets** | **$169,265** | **$171,168** | | **Total Current Liabilities** | $21,057 | $18,654 | | Long-term debt, net | $25,127 | $30,816 | | **Total Liabilities** | **$49,981** | **$54,170** | | **Total Stockholders' Equity** | **$119,284** | **$116,998** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net revenue increased significantly in Q2 2025, leading to a **$1.5 million** net income compared to a prior-year loss, with six-month net loss narrowing Statements of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Revenue** | $29,195 | $18,812 | $51,123 | $38,502 | | **Gross Profit** | $18,635 | $11,704 | $31,979 | $23,907 | | **Income (Loss) from Operations** | $3,189 | $(3,749) | $1,075 | $(8,778) | | **Net Income (Loss)** | **$1,532** | **$(4,008)** | **$(667)** | **$(10,908)** | | **Diluted EPS** | $0.08 | $(0.22) | $(0.04) | $(0.60) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities significantly improved to **$8.4 million** for the six months ended June 30, 2025, increasing cash and cash equivalents Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net Cash Provided by Operating Activities | $8,425 | $2,900 | | Net Cash Used in Investing Activities | $(128) | $(238) | | Net Cash Used in Financing Activities | $(5,092) | $(1,555) | | **Net Increase in Cash** | **$3,205** | **$1,107** | | **Cash and Cash Equivalents - End of Period** | **$16,585** | **$14,959** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's business, accounting policies, term loan, revenue recognition, stock-based compensation, and future payment commitments - The company operates as a single reportable segment, connecting life science companies with healthcare providers (HCPs) and patients through its technology platform[23](index=23&type=chunk)[27](index=27&type=chunk) - As of June 30, 2025, the company had a term loan with an outstanding principal of **$29.3 million**, bearing interest at **13.1%** and was in compliance with all financial covenants[39](index=39&type=chunk)[45](index=45&type=chunk)[47](index=47&type=chunk) - Revenue is primarily generated from content delivery activities and data subscriptions, recognized over time as services are performed, with **$6.3 million** recognized as an agent on a net basis for the first six months of 2025[69](index=69&type=chunk)[75](index=75&type=chunk)[77](index=77&type=chunk) - The company has commitments for future minimum payments to partners totaling **$13.1 million**, with **$7.6 million** due in the remainder of 2025[95](index=95&type=chunk) [Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting strong revenue growth, improved profitability, key performance indicators, and sufficient liquidity for the next twelve months [Overview and Strategy](index=24&type=section&id=Overview%20and%20Strategy) OptimizeRx, a digital healthcare technology company, employs a 'land and expand' strategy focusing on enterprise engagements and AI-powered solutions to drive growth - The company's core business is connecting life science organizations with over **two million HCPs** and their patients via an intelligent technology platform[106](index=106&type=chunk) - The strategy focuses on a "land and expand" model, aiming for enterprise-level engagements and promoting higher-margin, proprietary solutions like the AI-powered Dynamic Audience Activation Platform (DAAP)[108](index=108&type=chunk)[109](index=109&type=chunk) [Key Performance Indicators](index=24&type=section&id=Key%20Performance%20Indicators) Key performance indicators show increased average revenue per top 20 pharma manufacturer and improved revenue per employee, alongside strong net revenue retention Key Performance Indicators (Rolling Twelve Months Ended June 30) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Average revenue per top 20 pharma manufacturer (in thousands) | $3,082 | $2,753 | | % of total revenue from top 20 pharma manufacturers | 59% | 66% | | Net revenue retention | 121% | 124% | | Revenue per average full-time employee (in thousands) | $767 | $658 | [Results of Operations](index=26&type=section&id=Results%20of%20Operations) Net revenue grew **55%** in Q2 2025, improving gross margin and leading to a **$1.5 million** net income, primarily due to reduced stock-based compensation - Net revenue increased **55%** to **$29.2 million** for Q2 2025 and **33%** to **$51.1 million** for the six months ended June 30, 2025, driven by growth in DTC and DAAP related sales[121](index=121&type=chunk) - Gross margin improved to **63.8%** in Q2 2025 from **62.2%** in Q2 2024, attributed to a better product and channel partner mix[124](index=124&type=chunk) - Stock-based compensation expense decreased significantly to **$1.5 million** in Q2 2025 from **$2.9 million** in Q2 2024, mainly due to lower grant date fair values and forfeiture of prior CEO's awards[126](index=126&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with **$33.0 million** in working capital and expects existing cash and operations to fund obligations for the next twelve months - The company had working capital of **$33.0 million** and cash of **$16.6 million** as of June 30, 2025[134](index=134&type=chunk) - Management believes existing cash and funds from operations are sufficient to finance operations and meet obligations for the next 12 months[135](index=135&type=chunk) - Net cash from operating activities for the first six months of 2025 was **$8.4 million**, a significant increase from **$2.9 million** in the same period of 2024[137](index=137&type=chunk) [Item 4: Controls and Procedures](index=30&type=section&id=Item%204%3A%20Controls%20and%20Procedures) Disclosure controls and procedures were deemed ineffective due to an un-remediated material weakness concerning third-party data completeness and accuracy, with remediation efforts ongoing - Management concluded that disclosure controls and procedures were not effective as of the end of the period covered by the report[147](index=147&type=chunk) - The ineffectiveness is due to a previously identified material weakness related to controls over the completeness and accuracy of data received from third-party service organizations[147](index=147&type=chunk)[149](index=149&type=chunk) - Remediation efforts are underway, including requiring SOC-1, Type 2 audit reports from third parties, hiring a Senior VP of Internal Controls, and developing a new audit process; the material weakness will be considered remediated once new controls are tested and proven effective over time[150](index=150&type=chunk)[152](index=152&type=chunk)[153](index=153&type=chunk) [PART II — OTHER INFORMATION](index=32&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Item 1: Legal Proceedings](index=32&type=section&id=Item%201%3A%20Legal%20Proceedings) The company is not currently a party to any material legal or administrative proceedings, nor is it aware of any threatened actions - The company is not currently a party to any material legal proceedings[159](index=159&type=chunk) [Item 1A: Risk Factors](index=32&type=section&id=Item%201A%3A%20Risk%20Factors) No material changes to the risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K have occurred - No material changes in risk factors have occurred since the filing of the 2024 Annual Report on Form 10-K[160](index=160&type=chunk) [Item 5: Other Information](index=32&type=section&id=Item%205%3A%20Other%20Information) This section discloses the adoption of Rule 10b5-1 trading plans by executives and the approval of amended bylaws with new stockholder procedural requirements - During Q2 2025, director Patrick Spangler and CFO/COO Edward Stelmakh adopted Rule 10b5-1 trading plans for the sale of company securities[163](index=163&type=chunk)[164](index=164&type=chunk) - On August 5, 2025, the Board approved the Fourth Amended and Restated Bylaws, which established new and more detailed procedural requirements for stockholder nominations and business proposals[166](index=166&type=chunk)[167](index=167&type=chunk)

Financial Data and Key Metrics Changes - Q2 2025 revenues increased by 55% year over year to $29.2 million, with adjusted EBITDA at $5.8 million, an improvement of over $5 million year over year [3][11] - Gross margin increased from 62.2% in Q2 2024 to 63.8% in Q2 2025, attributed to a favorable product mix and economies of scale [10][11] - Net income for Q2 2025 was $1.5 million, compared to a net loss of $4 million in Q2 2024 [11] Business Line Data and Key Metrics Changes - Average revenue per top 20 pharmaceutical manufacturer is now $3.1 million, with a net revenue retention rate of 121% [13] - Average revenue over the last twelve months for the largest five customers is over $11 million [6] Market Data and Key Metrics Changes - Contracted revenue increased by more than 30% year over year, indicating strong market demand [4][34] - The company is positioned uniquely in the market, capable of engaging providers and patients at scale, leveraging a large point of care network [7][8] Company Strategy and Development Direction - The company is focused on operational excellence and strengthening relationships with business partners, aiming for sustainable long-term shareholder growth [3][6] - A key focus will be on addressing commercialization challenges in the pharmaceutical industry, including improving brand visibility and reducing script abandonment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving updated revenue guidance of $104 million to $108 million for the year, with promising initial indications for 2026 [4][5] - The company is not expecting to access equity capital markets for the foreseeable future due to strong free cash flow [5] Other Important Information - The company paid down $4.5 million of principal during Q2, exceeding its debt payment schedule by $4 million [5][12] - The company is committed to maintaining a healthy balance sheet to support operational goals [12] Q&A Session Summary Question: Revenue cadence and outliers in Q2 - Management acknowledged some managed service revenue contributed to Q2 results but maintained that guidance remains conservative and achievable [16][18] Question: Operating expenses sustainability - Management indicated that operating expenses are expected to remain flat in the second half of the year, reflecting operational leverage [20][22] Question: Growth in non-top 20 revenues - Management confirmed that revenues from non-top 20 clients are growing faster, with mid-sized accounts contributing positively [23][24] Question: Contracted revenue details - Management stated that contracted revenue is a blend of HCP and DTC business, both growing solidly, with no significant changes in contract lengths [34][35] Question: Subscription revenue percentage - Management indicated that subscription revenue is projected to reach about 10% for the year, assuming pipeline conversions [43] Question: Visibility on contracted revenue - Management confirmed contracted revenue is up 30% year over year, providing confidence in guidance for the fourth quarter [48][50] Question: Impact of managed services on Q2 performance - Management clarified that while managed services contributed to Q2, it was not the primary driver of performance [51][53] Question: Operating expenses and growth leverage - Management expects to maintain current operating expenses while being able to support significant revenue growth without major increases in headcount [55][56] Question: Pharma industry trends - Management noted that pharma companies are focusing on efficient revenue generation and are increasingly leaning into digital channels [58][60] Question: Pull forward of spending - Management reported no signs of pull forward in revenue but noted earlier engagement in planning for the second half [64][66]

[Second Quarter 2025 Financial Results Overview](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results%20Overview) OptimizeRx reported strong Q2 2025 results with significant revenue and profit growth, positive GAAP net income, accelerated debt repayment, and increased full-year guidance [Financial Highlights & Management Commentary](index=1&type=section&id=Financial%20Highlights%20%26%20Management%20Commentary) OptimizeRx reported strong Q2 2025 results with a 55% year-over-year revenue increase to $29.2 million and a 59% rise in gross profit to $18.6 million. The company achieved a GAAP net income of $1.5 million, a significant turnaround from a $4.0 million loss in the prior year. Management highlighted profitable growth driven by operational excellence and AI technology, noting that contracted revenue is up over 30% YoY. A key operational achievement was the accelerated repayment of $4.5 million in debt Q2 2025 vs Q2 2024 Financial Performance | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Revenue** | $29.2 million | $18.8 million | +55% | | **Gross Profit** | $18.6 million | $11.7 million | +59% | | **GAAP Net Income (Loss)** | $1.5 million | $(4.0) million | N/A | | **GAAP EPS (diluted)** | $0.08 | $(0.22) | N/A | | **Non-GAAP Net Income** | $4.5 million | $0.3 million | +1400% | | **Adjusted EBITDA** | $5.8 million | $0.5 million | +1064% | - Management attributes the strong performance to a disciplined focus on operational excellence, exceptional customer experiences, the use of market-leading patient-finding AI technology, and deepening ecosystem partnerships[3](index=3&type=chunk) - The company paid down **$4.5 million** of principal on its term loan during Q2, which was **$4.0 million** ahead of its debt payment schedule, and intends to continue accelerated repayments[1](index=1&type=chunk)[5](index=5&type=chunk) [Key Performance Indicators (KPIs)](index=2&type=section&id=Key%20Performance%20Indicators%20(KPIs)) For the twelve months ending June 30, 2025, net revenue retention stood strong at 121%. The company saw an increase in average revenue per top 20 pharmaceutical manufacturer to $3.08 million and improved operational efficiency, with revenue per average full-time employee rising to $767,000 Key Performance Indicators (Rolling Twelve Months Ended June 30) | KPI | 2025 | 2024 | | :--- | :--- | :--- | | **Average revenue per top 20 pharma manufacturer** | $3,082,000 | $2,753,000 | | **Percent of revenue from top 20 pharma manufacturers** | 59% | 66% | | **Net revenue retention** | 121% | 124% | | **Revenue per average full-time employee** | $767,000 | $658,000 | - The definition for "top 20 pharmaceutical manufacturers" was updated to be based on Fierce Pharma's 2024 revenue list, with prior periods restated for comparability[12](index=12&type=chunk)[13](index=13&type=chunk) [Fiscal Year 2025 Financial Outlook](index=2&type=section&id=Fiscal%20Year%202025%20Financial%20Outlook) Following strong year-to-date performance, OptimizeRx has increased its full-year 2025 financial guidance. The company now projects higher revenue and Adjusted EBITDA ranges for the fiscal year Updated Full Year 2025 Guidance | Metric | New Guidance Range | | :--- | :--- | | **Revenue** | $104 million - $108 million | | **Adjusted EBITDA** | $14.5 million - $17.5 million | [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents OptimizeRx's condensed consolidated financial statements, detailing the company's balance sheet, income statement, and cash flow performance for Q2 and H1 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, OptimizeRx's balance sheet showed total assets of $169.3 million and total liabilities of $50.0 million. Cash and cash equivalents increased to $16.6 million from $13.4 million at the end of 2024, while long-term debt, net of current portion, was reduced to $25.1 million from $30.8 million Balance Sheet Summary (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $16,585 | $13,380 | | **Total current assets** | $54,080 | $53,971 | | **Total Assets** | $169,265 | $171,168 | | **Long-term debt, net** | $25,127 | $30,816 | | **Total Liabilities** | $49,981 | $54,170 | | **Total stockholders' equity** | $119,284 | $116,998 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the second quarter of 2025, the company generated net revenue of $29.2 million, resulting in a gross profit of $18.6 million. This led to an income from operations of $3.2 million and a net income of $1.5 million, or $0.08 per diluted share, marking a significant improvement from the net loss of $4.0 million in Q2 2024 Q2 Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net revenue** | $29,195 | $18,812 | | **Gross profit** | $18,635 | $11,704 | | **Income (loss) from operations** | $3,189 | $(3,749) | | **Net income (loss)** | $1,532 | $(4,008) | | **Income (loss) per share – diluted** | $0.08 | $(0.22) | Six Months Statement of Operations Summary (in thousands, except per share data) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | **Net revenue** | $51,123 | $38,502 | | **Gross profit** | $31,979 | $23,907 | | **Income (loss) from operations** | $1,075 | $(8,778) | | **Net income (loss)** | $(667) | $(10,908) | | **Income (loss) per share – diluted** | $(0.04) | $(0.60) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the first six months of 2025, net cash provided by operating activities was $8.4 million, a significant increase from $2.9 million in the same period of 2024. The company used $5.1 million in financing activities, which included a $5.0 million repayment of long-term debt. This resulted in a net increase in cash and cash equivalents of $3.2 million Six Months Cash Flow Summary (in thousands) | Activity | H1 2025 | H1 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $8,425 | $2,900 | | **Net cash used in investing activities** | $(128) | $(238) | | **Net cash used in financing activities** | $(5,092) | $(1,555) | | **Net increase in cash and cash equivalents** | $3,205 | $1,107 | | **Cash and cash equivalents - end of period** | $16,585 | $14,959 | - The primary financing activity during the first six months of 2025 was the repayment of **$5.0 million** in long-term debt[25](index=25&type=chunk) [Non-GAAP Financial Measures](index=11&type=section&id=Non-GAAP%20Financial%20Measures) This section provides reconciliations of GAAP financial measures to Non-GAAP measures, including Non-GAAP Net Income and Adjusted EBITDA, detailing adjustments for non-cash items [Reconciliation of GAAP to Non-GAAP Net Income](index=11&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Net%20Income) The company's Non-GAAP net income for Q2 2025 was $4.5 million ($0.24 per diluted share), a substantial increase from $0.3 million ($0.02 per diluted share) in Q2 2024. The reconciliation from GAAP net income involved adjusting for non-cash items like depreciation & amortization ($1.1 million) and stock-based compensation ($1.5 million), among others Q2 GAAP to Non-GAAP Net Income Reconciliation (in thousands) | Description | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net income (loss) (GAAP)** | $1,532 | $(4,008) | | Depreciation and amortization | $1,074 | $1,073 | | Stock-based compensation | $1,488 | $2,903 | | Amortization of debt issuance costs | $437 | $182 | | Other adjustments | $(37) | $166 | | **Non-GAAP net income** | $4,494 | $316 | [Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA](index=12&type=section&id=Reconciliation%20of%20GAAP%20Net%20Income%20(Loss)%20to%20Adjusted%20EBITDA) Adjusted EBITDA for Q2 2025 surged to $5.8 million, compared to $0.5 million in the same period of 2024. This non-GAAP measure is derived by adjusting GAAP net income for interest, taxes, depreciation, amortization, stock-based compensation, and other non-recurring or non-cash items Q2 GAAP Net Income to Adjusted EBITDA Reconciliation (in thousands) | Description | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net income (loss) (GAAP)** | $1,532 | $(4,008) | | Depreciation and amortization | $1,074 | $1,073 | | Income tax (benefit) expense | $181 | $(1,088) | | Stock-based compensation | $1,488 | $2,903 | | Interest expense, net | $1,513 | $1,422 | | Other adjustments | $(37) | $166 | | **Adjusted EBITDA** | $5,751 | $468 | [Company Information and Forward-Looking Statements](index=3&type=section&id=Company%20Information%20and%20Forward-Looking%20Statements) This section provides an overview of OptimizeRx's business and includes important cautions regarding forward-looking statements and associated risks [About OptimizeRx](index=3&type=section&id=About%20OptimizeRx) OptimizeRx is a healthcare technology company focused on connecting life science brands with patients and healthcare providers. Its platform utilizes AI-driven tools, such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT), to facilitate timely and relevant engagement, aiming to accelerate treatment decisions and improve patient outcomes - The company's core business involves providing an AI-driven technology platform to create synchronized marketing solutions for life science brands, bridging the gap between healthcare professional (HCP) and direct-to-consumer (DTC) strategies[15](index=15&type=chunk) [Important Cautions Regarding Forward-Looking Statements](index=3&type=section&id=Important%20Cautions%20Regarding%20Forward-Looking%20Statements) This section provides a standard safe harbor statement, cautioning that the press release contains forward-looking statements, including financial guidance and plans for growth. It warns that these statements are based on current expectations and are subject to significant risks and uncertainties that could cause actual results to differ materially - Forward-looking statements in the report include expectations for future revenue, Adjusted EBITDA, plans to become a "**Rule of 40**" company, and intentions to pay down debt at an accelerated rate[17](index=17&type=chunk) - Investors are cautioned not to place undue reliance on these statements as they are subject to risks such as government regulation, cybersecurity incidents, and competition[17](index=17&type=chunk)

OptimizeRX (OPRX) is a Zacks Rank #1 (Strong Buy) that has an F for Value and an A for Growth. The company runs a health solutions platform that helps physicians and patients better afford and comply with their medicines and healthcare products. The company is expected to report earnings on 8/7, so now is a great time to take a look at this small cap company. Let's learn more about why this stock is the Bull of the Day. Description Estimates are moving higher for OptimizeRX (OPRX) . The full year 2025 has i ...

OptimizeRx (OPRX) - OptimizeRx is establishing a secure niche in the HealthTech landscape, showing a developing moat based on scale, data, and execution, with double-digit top-line growth over the last two quarters [1][8] - The company's transition from transactional to subscription-based revenues is projected to account for 5% of 2025's revenues, enhancing visibility and margin structure [1][8] - The core strength of OptimizeRx lies in its proprietary omnichannel platform that integrates point-of-care and direct-to-consumer marketing, leading to a 25% average script lift and ROIs exceeding 10:1 on six-month campaigns [2][8] - The net revenue retention rate has improved to 121% in fiscal 2024 and 114% in the first quarter of fiscal 2025, indicating strong client relationships and growing revenue per top client [2][8] - The company's competitive edge is supported by its data-rich execution and the ability to target both healthcare professionals and consumers effectively [3] - Gross margins were 68.2% in Q4 fiscal 2024 but decreased to 60.9% in Q1 fiscal 2025 due to increased DTC managed services, highlighting margin volatility [4][8] - Overall, OptimizeRx is solidifying its moat through a unique value proposition and growing recurring revenues, with sustained execution being crucial for future success [5] Doximity (DOCS) - Doximity's defensibility is anchored in its professional network of over 2 million verified U.S. medical professionals, resembling a LinkedIn for doctors [6] - The company is focusing on product innovation within core workflow tools, leading to a 20% year-over-year revenue increase with larger average contract sizes [6] - Doximity is expanding into new verticals in payer and hospital systems, indicating potential growth opportunities beyond pharma [6] Veeva Systems (VEEV) - Veeva's moat is based on its vertical SaaS dominance in life sciences, with a reported 16.7% year-over-year revenue growth in Q1 fiscal 2026 [7] - The company is migrating to Vault CRM and aims for 200 live customers by next year, with its data and audience measurement unit, Crossix, growing over 30% year over year [7] - Veeva AI is being integrated into core products to achieve over 15% productivity gains by 2030, enhancing customer stickiness [7]